Pharmaceutical executives and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said Thursday that the industry expects it will take 12 to 18 months to launch a coronavirus vaccine, as reported FRANCE 24.
While bureaucracy could be slashed to speed up the process, the time needed for safety testing could not be compromised, they said.
"We're confident technology will arrest this disease," said Eli Lilly chairman and IFPMA president David Ricks, but added that "this is not a capital resource problem right now, more of a human resource problem."
David Loew, the executive vice president of Sanofi, noted that "when you think about how many people we will want to vaccinate -- once we have a vaccine -- around the world, we're talking billions, and that's a huge challenge," adding that "we need to ensure the safety. It's going to take 12 to 18 months until you have a registered vaccine on the market."
Rajeev Venkayya, president of the global vaccines business unit at Takeda, said that timeline was "very aggressive but we think it might be feasible," adding that the value of running multiple trials simultaneously was that "some will succeed and get across the finish line."
Paul Stoffels, chief scientific officer at Johnson and Johnson, said "it's a new virus which needs new tools, and that's where we have to start from scratch on the research," but added that "the industry would ensure that any vaccine, wherever it is produced, "will be available" to everyone "who needs it" across the globe.
To read more NewsPoints articles, click here.